Skip to content
Back to CLNN

Clene Inc.

Open-market purchases and sales reported on SEC Forms 4 and 5, with each filing and its footnotes.

Since Nov 18, 2025
Transactions
63
Purchases
1
Sales
62
Purchase value
$216.66K
Sale value
$5.78M

Values are shares multiplied by reported price when both were supplied, each trade counted once however many filers reported it.

Ugwumba Chidozie10% owner
4
Filed May 13, 2026Period of report May 11, 20130001835544-26-000019
TransactionSecuritySharesPriceValueHeld afterOwnership
SaleMay 12, 2026
Common Stock73,296$6.20$454.44K103,417IndirectBy SymBiosis II, LLC
SaleMay 11, 2026
Common Stock22,177$6.75$149.69K176,713IndirectBy SymBiosis II, LLC
Open on SEC EDGAR
Ugwumba Chidozie10% owner
4
Filed May 5, 2026Period of report May 1, 20260001835544-26-000018
TransactionSecuritySharesPriceValueHeld afterOwnership
SaleMay 4, 2026
Common Stock72,884$6.80$495.61K198,890IndirectBy SymBiosis II, LLC
SaleMay 1, 2026
Common Stock5,795$6.01$34.83K271,774IndirectBy SymBiosis II, LLC
Open on SEC EDGAR
Ugwumba Chidozie10% owner
4
Filed Apr 30, 2026Period of report Apr 28, 20260001835544-26-000017
TransactionSecuritySharesPriceValueHeld afterOwnership
SaleApr 30, 2026
Common Stock5,736$6.08$34.87K277,569IndirectBy SymBiosis II, LLC
SaleApr 29, 2026
Common Stock12,170$5.63$68.52K283,305IndirectBy SymBiosis II, LLC
SaleApr 28, 2026
Common Stock1,591$5.90$9.39K295,475IndirectBy SymBiosis II, LLC
Open on SEC EDGAR
Ugwumba Chidozie10% owner
4
Filed Apr 22, 2026Period of report Apr 20, 20260001835544-26-000016
TransactionSecuritySharesPriceValueHeld afterOwnership
SaleApr 21, 2026
Common Stock61,345$6.14$376.66K297,066IndirectBy SymBiosis II, LLC
SaleApr 20, 2026
Common Stock4,318$6.12$26.43K358,411IndirectBy SymBiosis II, LLC
Open on SEC EDGAR
Ugwumba Chidozie10% owner
4
Filed Apr 17, 2026Period of report Apr 15, 20260001835544-26-000015
TransactionSecuritySharesPriceValueHeld afterOwnership
SaleApr 17, 2026
Common Stock25,040$6.43$161.01K362,729IndirectBy SymBiosis II, LLC
SaleApr 16, 2026
Common Stock7,748$6.40$49.59K387,769IndirectBy SymBiosis II, LLC
SaleApr 15, 2026
Common Stock6,374$6.48$41.30K395,517IndirectBy SymBiosis II, LLC
Open on SEC EDGAR
Ugwumba Chidozie10% owner
4
Filed Apr 6, 2026Period of report Apr 2, 20260001835544-26-000014
TransactionSecuritySharesPriceValueHeld afterOwnership
SaleApr 2, 2026
Common Stock24,925$4.81$119.89K401,891IndirectBy SymBiosis II, LLC
Open on SEC EDGAR
Ugwumba Chidozie10% owner
4
Filed Apr 1, 2026Period of report Apr 1, 20260001835544-26-000013
TransactionSecuritySharesPriceValueHeld afterOwnership
SaleApr 1, 2026
Common Stock4,278$4.97$21.26K426,816IndirectBy SymBiosis II, LLC
Open on SEC EDGAR
Ugwumba Chidozie10% owner
4
Filed Mar 31, 2026Period of report Mar 27, 20260001835544-26-000012
TransactionSecuritySharesPriceValueHeld afterOwnership
SaleMar 31, 2026
Common Stock67,991$4.88$331.80K431,094IndirectBy Symbiosis II, LLC
SaleMar 30, 2026
Common Stock15,536$5.10$79.23K499,085IndirectBy SymBiosis II, LLC
SaleMar 27, 2026
Common Stock17,470$4.75$82.98K514,621IndirectBy SymBiosis II, LLC
Open on SEC EDGAR
Ugwumba Chidozie10% owner
4
Filed Mar 26, 2026Period of report Mar 24, 20260001835544-26-000011
TransactionSecuritySharesPriceValueHeld afterOwnership
SaleMar 26, 2026
Common Stock5,319$5.40$28.72K532,091IndirectBy SymBiosis II, LLC
SaleMar 25, 2026
Common Stock7,098$5.50$39.04K537,410IndirectBy SymBiosis II, LLC
SaleMar 24, 2026
Common Stock5,492$5.78$31.74K544,508IndirectBy SymBiosis II, LLC
Open on SEC EDGAR
Ugwumba Chidozie10% owner
4
Filed Feb 5, 2026Period of report Feb 3, 20260001835544-26-000010
TransactionSecuritySharesPriceValueHeld afterOwnership
SaleFeb 3, 2026
Common Stock5,559$4.10$22.79K550,000IndirectBy Symbiosis II, LLC
Open on SEC EDGAR
Ugwumba Chidozie10% owner
4
Filed Feb 2, 2026Period of report Jan 29, 20260001835544-26-000009
TransactionSecuritySharesPriceValueHeld afterOwnership
SaleFeb 2, 2026
Common Stock3,800$4.04$15.35K555,559IndirectBy SymBiosis II, LLC
SaleJan 30, 2026
Common Stock5,686$4.13$23.48K559,359IndirectBy Symbiosis II, LLC
SaleJan 29, 2026
Common Stock15,284$4.32$66.03K565,045IndirectBy Symbiosis II, LLC
Open on SEC EDGAR
Ugwumba Chidozie10% owner
4
Filed Jan 28, 2026Period of report Jan 26, 20260001835544-26-000008
TransactionSecuritySharesPriceValueHeld afterOwnership
SaleJan 28, 2026
Common Stock8,717$4.91$42.80K580,329IndirectBy SymBiosis II, LLC
SaleJan 27, 2026
Common Stock4,139$5.08$21.03K589,046IndirectBy Symbiosis II, LLC
SaleJan 26, 2026
Common Stock6,418$5.02$32.22K593,185IndirectBy Symbiosis II, LLC
Open on SEC EDGAR
Ugwumba Chidozie10% owner
4
Filed Jan 23, 2026Period of report Jan 22, 20260001835544-26-000007
TransactionSecuritySharesPriceValueHeld afterOwnership
SaleJan 23, 2026
Common Stock5,556$5.27$29.28K599,603IndirectBy Symbiosis II, LLC
SaleJan 22, 2026
Common Stock12,665$5.32$67.38K605,159IndirectBy Symbiosis II, LLC
Open on SEC EDGAR
Ugwumba Chidozie10% owner
4
Filed Jan 21, 2026Period of report Jan 16, 20260001835544-26-000006
TransactionSecuritySharesPriceValueHeld afterOwnership
SaleJan 21, 2026
Common Stock12,119$5.05$61.20K617,824IndirectBy Symbiosis II, LLC
SaleJan 20, 2026
Common Stock12,432$4.80$59.67K629,943IndirectBy Symbiosis II, LLC
SaleJan 16, 2026
Common Stock7,923$5.13$40.64K642,375IndirectBy Symbiosis II, LLC
Open on SEC EDGAR
Ugwumba Chidozie10% owner
4
Filed Jan 16, 2026Period of report Jan 13, 20260001835544-26-000005
TransactionSecuritySharesPriceValueHeld afterOwnership
SaleJan 15, 2026
Common Stock12,563$5.10$64.07K650,298IndirectBy Symbiosis II, LLC
SaleJan 14, 2026
Common Stock19,621$5.12$100.46K662,861IndirectBy Symbiosis II, LLC
SaleJan 13, 2026
Common Stock26,105$4.89$127.65K682,482IndirectBy Symbiosis II, LLC
Open on SEC EDGAR
David J MatlinDirector
4
Filed Jan 13, 2026Period of report Jan 13, 20260001437749-26-001170
TransactionSecuritySharesPriceValueHeld afterOwnership
PurchaseJan 13, 2026
common stockF1F233,333$6.50$216.66K477,824Direct
Filing footnotes · 6
  1. F1The reporting person entered into a Securities Purchase Agreement with Clene Inc. and the other parties thereto, dated January 8, 2026, for the purchase of 33,333 shares of the Company's common stock, Series A Warrants to purchase 40,000 shares of the Company's common stock and Series B Warrants to purchase 93,333 shares of the Company's common stock, closing effective January 13, 2026.
  2. F2The price of each Unit is $6.50 consisting of one share of Common Stock of Clene, one Series A Warrant and one Series B Warrant.
  3. F3The exercise price of each Series A Warrant will increase from $6.00 to $7.00 per share if either: (a) the warrant is exercised prior to the Company's public announcement of the U.S. Food and Drug Administration's (the "FDA") posted action date under the Prescription Drug User Fee Act for the Company's new drug application ("NDA") for CNM-Au8 (the "Series A Trigger Announcement "); or (b) the volume-weighted average price (the "VWAP") of the Company's common stock equals or exceeds $10.00 on the measurement date associated with the Series A Trigger Announcement.
  4. F4The reporting person will be entitled to purchase its pro rata share of the number of shares of common stock determined by dividing $6,684,000 by the applicable exercise price.
  5. F5The exercise price for each Series B Warrant will increase from $6.00 to $12.50 per share if: (i) the Series B Warrant is exercised prior to the Company's public announcement of its receipt of written approval from the FDA of its NDA for CNM-Au8 in ALS or (ii) the VWAP of the Company's common stock is equal to or greater than $25.00 on the associated measurement date. The exercise price of the Series B Warrant will increase to $10.00 per share if the VWAP of the Company's common stock is equal to or greater than $20.00 on the associated measurement date.
  6. F6The reporting person will be entitled to purchase its pro rata share of the number of shares of common stock determined by dividing $15,596,000 by the applicable exercise price.
Open on SEC EDGAR
Ugwumba Chidozie10% owner
4
Filed Jan 12, 2026Period of report Jan 8, 20260001835544-26-000003
TransactionSecuritySharesPriceValueHeld afterOwnership
SaleJan 12, 2026
Common Stock32,705$5.50$179.88K708,587IndirectBy Symbiosis II, LLC
SaleJan 9, 2026
Common Stock9,075$6.27$56.90K741,292IndirectBy Symbiosis II, LLC
SaleJan 8, 2026
Common Stock3,195$6.09$19.46K750,367IndirectBy Symbiosis II, LLC
Open on SEC EDGAR
Ugwumba Chidozie10% owner
4
Filed Jan 7, 2026Period of report Jan 5, 20260001835544-26-000002
TransactionSecuritySharesPriceValueHeld afterOwnership
SaleJan 7, 2026
Common Stock3,938$6.29$24.77K753,562IndirectBy Symbiosis II, LLC
SaleJan 6, 2026
Common Stock3,111$6.04$18.79K757,500IndirectBy Symbiosis II, LLC
SaleJan 5, 2026
Common Stock5,869$5.87$34.45K760,611IndirectBy Symbiosis II, LLC
Open on SEC EDGAR
Ugwumba Chidozie10% owner
4
Filed Jan 2, 2026Period of report Dec 31, 20250001835544-26-000001
TransactionSecuritySharesPriceValueHeld afterOwnership
SaleJan 2, 2026
Common Stock4,015$5.73$23.01K766,480IndirectBy Symbiosis II, LLC
SaleDec 31, 2025
Common Stock13,095$5.81$76.08K770,495IndirectBy Symbiosis II, LLC
Open on SEC EDGAR
Ugwumba Chidozie10% owner
4
Filed Dec 31, 2025Period of report Dec 29, 20250001835544-25-000006
TransactionSecuritySharesPriceValueHeld afterOwnership
SaleDec 30, 2025
Common Stock4,138$6.03$24.95K783,590IndirectBy Symbiosis II, LLC
SaleDec 29, 2025
Common Stock8,096$5.95$48.17K787,728IndirectBy Symbiosis II, LLC
Open on SEC EDGAR
Ugwumba Chidozie10% owner
4
Filed Dec 30, 2025Period of report Dec 23, 20250001835544-25-000005
TransactionSecuritySharesPriceValueHeld afterOwnership
SaleDec 26, 2025
Common Stock3,350$6.32$21.17K795,824IndirectBy Symbiosis II, LLC
SaleDec 24, 2025
Common Stock1,490$6.27$9.34K799,174IndirectBy Symbiosis II, LLC
SaleDec 23, 2025
Common Stock6,831$6.27$42.83K800,664IndirectBy Symbiosis II, LLC
Filing footnotes · 2
  1. F1In connection with the cashless exercise of the pre-funded warrants, the issuer withheld shares of common stock to satisfy the $0.001 per-share exercise price, resulting in the issuance of fewer shares than the number of shares underlying the warrants exercised.
  2. F2The pre-funded warrants are indefinite with no specified termination date.
Open on SEC EDGAR
Ugwumba Chidozie10% owner
4
Filed Dec 23, 2025Period of report Dec 19, 20250001835544-25-000004
TransactionSecuritySharesPriceValueHeld afterOwnership
SaleDec 22, 2025
Common Stock4,367$6.54$28.56K383,201IndirectBy Symbiosis II, LLC
SaleDec 19, 2025
Common Stock5,582$6.45$36.00K387,568IndirectBy Symbiosis II, LLC
Open on SEC EDGAR
Ugwumba Chidozie10% owner
4
Filed Dec 18, 2025Period of report Dec 3, 20250001835544-25-000002
TransactionSecuritySharesPriceValueHeld afterOwnership
SaleDec 18, 2025
Common Stock5,816$6.33$36.82K393,150IndirectBy Symbiosis II, LLC
SaleDec 17, 2025
Common Stock2,884$6.61$19.06K398,966IndirectBy Symbiosis II, LLC
SaleDec 16, 2025
Common Stock7,030$6.31$44.36K401,850IndirectBy Symbiosis II, LLC
SaleDec 15, 2025
Common Stock10,580$6.49$68.66K408,880IndirectBy Symbiosis II, LLC
SaleDec 12, 2025
Common Stock7,603$6.79$51.62K419,460IndirectBy Symbiosis II, LLC
SaleDec 11, 2025
Common Stock10,907$6.81$74.28K427,063IndirectBy Symbiosis II, LLC
SaleDec 10, 2025
Common Stock9,921$6.42$63.69K437,970IndirectBy Symbiosis II, LLC
SaleDec 9, 2025
Common Stock15,031$5.95$89.43K447,891IndirectBy Symbiosis II, LLC
SaleDec 8, 2025
Common Stock21,463$5.70$122.34K462,922IndirectBy Symbiosis II, LLC
SaleDec 5, 2025
Common Stock37,235$5.94$221.18K484,385IndirectBy Symbiosis II, LLC
SaleDec 4, 2025
Common Stock72,748$6.73$489.59K521,620IndirectBy Symbiosis II, LLC
SaleDec 3, 2025
Common Stock56,577$7.86$444.70K594,368IndirectBy Symbiosis II, LLC
Open on SEC EDGAR

P and S transaction codes only. Grants, gifts, option exercises, tax withholding, and Form 144 notices are not counted as purchases or sales. A row whose filed price fails a plausibility check, or that is not common stock, is listed but left out of the values; a trade reported by several filers is counted once.